Abstract
Although haploidentical donor lymphocyte infusion (DLI) is a valid treatment option for relapsed acute myeloid leukemia (AML), the incidence and risk factors for graft-versus-host disease (GVHD) and the efficacy of haploidentical DLI have not been fully evaluated. We retrospectively analyzed the outcomes after haploidentical DLI for 84 patients with AML using a nationwide database and additional questionnaires. The median number of DLI cycles and infused CD3+ cell dose was 1 and 1.0 × 106/kg, respectively. The infused CD3+ cell count of 5.0 × 105/kg or higher was associated with acute GVHD (grade II–IV, 32.1% vs. 10.5%, p = 0.03; grade III–IV, 21.4% vs. 5.3%, p = 0.10). Patients who developed grade III–IV acute GVHD more frequently succumbed to treatment-related mortality (46.7% vs. 15.8% at 1 year, p = 0.002), although the relapse-related mortality was significantly low (40.0% vs. 72.2% at 1 year, p = 0.025). The overall response to DLI was significantly higher in the preemptive DLI group (47.4%) than in the therapeutic group (13.9%, p = 0.002). In the multivariate analysis, preemptive DLI was the predictive factor for overall response (odds ratio, 5.58; p = 0.003). Our results indicated the substantial risk of acute GVHD after haploidentical DLI with CD3+ cell count of 5.0×105/kg or higher and the favorable outcomes after preemptive DLI.
Similar content being viewed by others
References
Schmid C, Labopin M, Nagler A et al (2007) Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute leukemia Working Party. J Clin Oncol 25:4938–4945
Takami A, Yano S, Yokoyama H et al (2014) Donor lymphocyte infusion for the treatment of relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: a retrospective analysis by the adult acute myeloid leukemia working group of the Japan Society for Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 20:1785–1790
Miyamoto T, Fukuda T, Nakashima M et al (2017) Donor lymphocyte infusion for relapsed hematological malignancies after unrelated allogeneic bone marrow transplantation facilitated by the Japan Marrow Donor Program. Biol Blood Marrow Transplant 23:938–944
Hofmann S, Schmitt M, Götz M et al (2019) Donor lymphocyte infusion leads to diversity of specific T cell responses and reduces regulatory T cell frequency in clinical responders. Int J Cancer 144:1135–1146
Liu L, Chang YJ, Xu LP et al (2018) Reversal of T cell exhaustion by the first donor lymphocyte infusion is associated with the persistently effective antileukemic responses in patients with relapsed AML after allo-HSCT. Biol Blood Marrow Transplant 24:1350–1359
Chalandon Y, Passweg JR, Schmid C et al (2010) Outcome of patients developing GVHD after DLI given to treat CML relapse: a study by the chronic leukemia working party of the EBMT. Bone Marrow Transplant 45:558–564
Luznik L, O’Donnell PV, Symons HJ et al (2008) HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 14:641–650
Sugita J (2019) HLA-haploidentical stem cell transplantation using posttransplant cyclophosphamide. Int J Hematol 110:30–38
Baron F, Mohty M, Blaise D et al (2017) Anti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the acute leukemia working party of the European Society for Blood and Marrow Transplantation. Haematologica 102:224–234
Ikegame K, Yoshida T, Yoshihara S et al (2015) Unmanipulated haploidentical reduced-intensity stem cell transplantation using fludarabine, busulfan, low-dose antithymocyte globulin, and steroids for patients in non-complete remission or at high risk of relapse: A prospective multicenter Phase I/II study in Japan. Biol Blood Marrow Transplant 21:1495–1505
Zeidan AM, Forde PM, Symons H et al (2014) HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant 20:314–318
Ghiso A, Raiola AM, Gualandi F et al (2015) DLI after haploidentical BMT with post-transplant CY. Bone Marrow Transplant 50:56–61
Goldsmith SR, Slade M, DiPersio JF et al (2017) Donor-lymphocyte infusion following haploidentical hematopoietic cell transplantation with peripheral blood stem cell grafts and PTCy. Bone Marrow Transplant 52:1623–1628
Huang XJ, Liu DH, Liu KY et al (2007) Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation. Haematologica 92:414–417
Yan CH, Liu DH, Xu LP et al (2012) Modified donor lymphocyte infusion-associated acute graft-versus-host disease after haploidentical T-cell-replete hematopoietic stem cell transplantation: incidence and risk factors. Clin Transplant 26:868–876
Dholaria B, Savani BN, Labopin M et al (2020) Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the acute leukemia working party of the EBMT. Haematologica 105:47–58
Yan CH, Liu QF, Wu DP et al (2017) Prophylactic donor lymphocyte infusion (DLI) followed by minimal residual disease and graft-versus-host disease-guided multiple DLIs could improve outcomes after allogeneic hematopoietic stem cell transplantation in patients with refractory/relapsed acute leukemia. Biol Blood Marrow Transplant 23:1311–1319
Gao XN, Lin J, Wang LJ et al (2019) Comparison of the safety and efficacy of prophylactic donor lymphocyte infusion after haploidentical versus matched-sibling PBSCT in very high-risk acute myeloid leukemia. Ann Hematol 98:1267–1277
Yan CH, Xu LP, Liu DH et al (2015) Low-dose methotrexate may preserve a stronger antileukemic effect than that of cyclosporine after modified donor lymphocyte infusion in unmanipulated haploidentical HSCT. Clin Transplant 29:594–605
Atsuta Y (2016) Introduction of Transplant Registry Unified Management Program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data). Int J Hematol 103:3–10
Kanda J (2016) Scripts for TRUMP data analyses. part II (HLA-related data): statistical analyses specific for hematopoietic stem cell transplantation. Int J Hematol 103:11–19
Yanada M, Mori J, Aoki J et al (2018) Effect of cytogenetic risk status on outcomes for patients with acute myeloid leukemia undergoing various types of allogeneic hematopoietic cell transplantation: an analysis of 7812 patients. Leuk Lymphoma 59:601–609
nccn.org [internet]. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Acute Myeloid Leukemia. Version 2. 2021. Available from: https://www.nccn.org/professionals/physician_gls/default.aspx. Accessed 27 Feb 2021
Przepiorka D, Weisdorf D, Martin P, et al. (1995) 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 15:825–828
Sullivan KM, Agura E, Anasetti C et al (1991) Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 28:250–259
Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48:452–458
Battipaglia G, Labopin M, Kröger N et al (2019) Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation. Blood 134:892–899
Ruggeri A, Sun Y, Labopin M et al (2017) Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft- versus-host disease prophylaxis in haploidentical transplant. Haematologica 102:401–410
Eefting M, von dem Borne PA, de Wreede LC et al (2014) Intentional donor lymphocyte-induced limited acute graft-versus-host disease is essential for long-term survival of relapsed acute myeloid leukemia after allogeneic stem cell transplantation. Haematologica 99:751–758
Guillaume T, Malard F, Magro L et al (2019) Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplant 54:1815–1826
Chen YB, Li S, Lane AA et al (2014) Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia. Biol Blood Marrow Transplant 20:2042–2048
Sandmaier BM, Khaled S, Oran B et al (2018) Results of a phase 1 study of quizartinib as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic stem cell transplant. Am J Hematol 93:222–231
Acknowledgments
We are grateful to all physicians and staff at the transplant centers who provided the clinical data to the Transplant Registry Unified Management Program of the Japan Society of Hematopoietic Cell Transplantation. We also express gratitude to the staff at the Japan Society of Hematopoietic Cell Transplantation and the Japanese Data Center for Hematopoietic Cell Transplantation for their dedication to the organization and management of the data.
Funding
This work was supported in part by the Practical Research Project for Allergic Diseases and Immunology (Research Technology of Medical Transplantation) from Japan Agency for Medical Research and Development, AMED under Grant Number 18ek0510023h0002.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Ethics approval
Informed consent was obtained from all participants for inclusion in this study. This retrospective study was approved by the data management committees of the Transplant Registry Unified Management Program and the Institutional Review Board of Tokai University School of Medicine.
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Harada, K., Mizuno, S., Yano, S. et al. Donor lymphocyte infusion after haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia. Ann Hematol 101, 643–653 (2022). https://doi.org/10.1007/s00277-021-04731-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-021-04731-5